At Cytodigm, we are advancing three different #nanoparticle technologies through the clinic. Our lead candidate is #Zetafinity, which is a #PNP, and is in Phase 2 trials. Check out our #drugdelivery pipeline: https://lnkd.in/eHtAYbiB
Cytodigm
纳米技术研究
Natick，MA 231 位关注者
Biotech company with proprietary drug delivery systems (LNP and PNP) for targeted cell & gene therapies.
关于我们
Cytodigm is a biotechnology company with a pipeline of innovative non-viral drug delivery systems (DDS). These nanoparticle platform technologies support internal/co-development projects, as well as projects where Cytodigm out-licenses the DDS technology to external biopharmaceutical companies to support their Clinical Trials. The Cytodigm IP portfolio focuses on the compositions, methods of use, and manufacturing of DDS technologies. This includes 7 Granted Patents and 13 PCTs. Lead Nanoparticle Technologies: 1. Zetafinity (PNP) - A polymeric nanoparticle made of the polymer poly(lactic-co-glycolic) acid (PLGA). Currently in Takeda Phase 2 Clinical Trials. Licensing available for Oncology indicacations. 2. Cytofinity (LNP) - A lipid nanoparticle (LNP) incorporating a natural lipid-ganglioside as part of the formulation. What is unique about this formulation is that a ganglioside replaces the Polyethylene Glycol (PEG)-lipid. Further differentiations from other nanocarriers: (1) No need for a PEG-lipid, (2) Active Cell Targeting, (3) LNPs themselves are Anti-Inflammatory, and (4) Cytofinity LNPs remain intact after nebulization and can transfect the lungs. Cytodigm was founded in 2022 by Bin Wu, Ph.D. and is located in Boston, Massachusetts. He has over 20 years' of experience in biodegradable lipid nanoparticles (LNP), polymer nanoparticles (PNP), lipoplexes, and polymeric microparticles for the targeted delivery of nucleic acids, peptides, proteins, and small molecules. He is the inventor of over 20 US Patents and 30 International PCT Applications. Bin earned a Ph.D. in Polymer Chemistry from the University of Massachusetts Amherst. Cytodigm is supported by strong partnerships, scientists, and consultants that are strong players in the cell & gene therapy (CGT) space, both academia and industry. For inquiries, please reach out to [email protected]
- 所属行业
- 纳米技术研究
- 规模
- 2-10 人
- 总部
- Natick，MA
- 类型
- 私人持股
- 创立
- 2022
- 领域
- LNP、PNP、DDS、Lipid Nanoparticle、Polymer Chemistry、Drug Delivery、Biotechnology、Nanotechnology、Nanoparticle、Platform Technology、Licensing、Drug Development、Gene Therapy、Cell Therapy、Lipids、Polymers、Lipopolex、Cell Targeting、Precision Medicine、Lipid Screening、Molecular Biology和Lipidomics
地点
-
主要
获取路线
US，MA，Natick
Cytodigm员工
动态
-
We are happy to share our new website! Take a look! Now you can check out Cytodigm's technologies and pipeline as we look to continue to advance our non-viral drug delivery systems through the clinic. Zetafinity? is a novel polymer nanoparticle (#PNP) delivering small molecules, peptides, and protein therapeutics to immune cells. Several ongoing phase-2 clinical trials are using Zetafinity? technology to deliver proteins to antigen-presenting cells to treat #autoimmune diseases. Cytofinity? is a #LNP that was created by replacing PEG-lipid, a key component in traditional LNP formulations, with ganglioside, a natural lipid that contains sialic acid (Sia) ligands. The hydrophilic #Sia ligands are located on the surface of the LNPs and bind #Siglec receptors on different types of cells, facilitating cell and tissue targeting via receptor-mediated endocytosis. Sigfinity? is a #lipoplex (#LPP) consisting of a nucleic acid, a cationic lipid or polymer, and a surface coating of polymers containing a receptor-binding ligand such as polysialic acid (PSA). https://lnkd.in/ec_ebAH6
-
?? Exciting Highlights from the 3rd LNP Immunogenicity and Toxicity Summit! ?? We are delighted to share that our Founder and CEO, Dr. Bin Wu, presented Cytodigm's pioneering work on "PEG-free" lipid nanoparticles (LNPs) at the recent summit in #Boston. In his presentation, "Case Study: Building Next-Generation LNPs with Gangliosides Instead of PEG-Lipid to Reinvent Safety & Mitigate Immunogenicity," Dr. Wu introduced our innovative #Cytofinity? #LNP technology. This advanced platform incorporates ganglioside, a natural and endogenous lipid, as opposed to PEG-lipid, a key component in traditional LNPs, to eliminate PEG-mediated immunogenicity. Besides being PEG-free, Cytofinity? also stands out with its remarkable ability to target extrahepatic tissues and cells without needing antibody conjugation. Cytofinity’s diverse formulations can effectively deliver RNAs to the lung, bone marrow, T cells, and HSCs, broadening possibilities in nucleic acid-based therapies. We are excited about the transformative impact of Cytofinity? and look forward to exploring more opportunities to collaborate and innovate! #Innovation #Biotech #Drugdelivery #Lipidnanoparticle #Biotechnology #Nanotechnology #Therapeutics #DDS #immunogenicity #Biotechinnovation